Evidence map›Paper›PMID 36212980›Full record

ArticleEuropean urology open science2022

Intravesical Ty21a Treatment of Non-muscle-invasive Bladder Cancer Shows a Good Safety Profile.

Ilaria Lucca, Laurent Derré, Valérie Cesson, Perrine Bohner, François Crettenand, Sonia Rodrigues-Dias, Florence Dartiguenave, Audrey Masnada, Carla Texeira-Pereira, Sulayman Benmerzoug and 8 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European urology open science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Genetic engineering ofEcoSal Plus · 2024
    Review
  5. Review
  6. Bacteria-Based Nanoprobes for Cancer Therapy.International journal of nanomedicine · 2024
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 2 institutions in 1 country.

Ilaria LuccaDepartment of Urology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland.
Laurent DerréDepartment of Urology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland.
Valérie CessonDepartment of Urology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland.
Perrine BohnerDepartment of Urology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland.
François CrettenandDepartment of Urology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland.
Sonia Rodrigues-DiasDepartment of Urology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland.
Florence DartiguenaveDepartment of Urology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland.
Audrey MasnadaDepartment of Urology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland.
Carla Texeira-PereiraDepartment of Urology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland.
Sulayman BenmerzougDepartment of Urology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland.
Mathieu ChevalierDepartment of Urology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland.
Sonia Domingos-PereiraDepartment of Urology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland.
Sylvain NguyenDepartment of Urology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland.
Lenka PolakDepartment of Urology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland.
Anna SchneiderDepartment of Urology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland.
Beat RothDepartment of Urology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland.
Patrice JichlinskiDepartment of Urology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland.
Denise Nardelli-HaefligerDepartment of Urology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland.
University Hospital of Lausanne · CHUniversity of Lausanne · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Standard-of-care immunotherapy for non-muscle-invasive bladder cancer (NMIBC) with intravesical Bacillus Calmettte Patient summary: We examined the safety of a new intra-bladder immunotherapy for non-muscle-invasive bladder cancer as an alternative to the standard BCG treatment. Our data show that the Ty21a vaccine might be well tolerated. Further studies are needed to determine the safety and antitumor efficacy of this treatment.

Indexed as

Intravesical microbial immunotherapyNon–muscle-invasive bladder cancerPhase 1 trialSalmonella Ty21a

Identifiers

PMID36212980
PMCPMC9539774
OpenAlexW4300970698

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.